大腸がんスクリーニングと診断市場- 世界の産業規模、シェア、動向、機会、予測、スクリーニング別、診断別、エンドユーザー別、地域別、競合別セグメント、2020-2030F

大腸がんスクリーニングと診断の世界市場は、2024年に150億8,000万米ドルと評価され、2030年までのCAGRは5.34%で、予測期間には206億3,000万米ドルに達すると予測されています。

大腸がんスクリーニングと診断の世界市場は、がん予防、早期発見、診断技術の進歩に関する世界の意識の高まりにより、著しい成長を遂げています。特に50歳以上の大腸がん罹患率の上昇が、早期かつ正確なスクリーニング法の需要を促進しています。政府やヘルスケア機関は、定期的なスクリーニングの重要性を強調する啓発キャンペーンを開始し、検査件数の急増に寄与しています。官民パートナーシップとヘルスケア資金イニシアティブにより、特に十分なサービスを受けていない集団において、診断サービスへのアクセス拡大が可能になっています。さらに、糞便免疫化学検査（FIT）、糞便DNA検査、血液ベースの診断などの非侵襲的スクリーニング法が受け入れられつつあることで、スクリーニングがより身近なものとなり、より幅広い患者層に受け入れられるようになっています。

技術革新が市場展望の再形成に重要な役割を果たしています。AIベースの大腸内視鏡システム、デジタル病理学ツール、リキッドバイオプシー技術の開発により、検出精度が向上し、侵襲的処置の必要性が減少しています。画像診断における機械学習の統合は、ポリープや早期腫瘍をより効果的に特定する上で臨床医を支援しています。在宅検査やポイント・オブ・ケア検査への関心の高まりは、患者行動にも変化をもたらしており、より多くの個人が便利な自己診断ツールを選択しています。主要診断企業は、より高い特異性と感度を提供するバイオマーカーベースのスクリーニングアプローチを強化するための研究に投資しており、これが新たな収益源を開拓しています。大腸がんマーカーを含むマルチがん検出パネルの出現は、業界内のイノベーションと競合をさらに活性化すると予想されます。

主要市場促進要因

技術の進歩

主な市場課題

偽陽性と過剰診断

主要市場動向

非侵襲的検査へのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の大腸がんスクリーニングと診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • スクリーニング（便検査、大腸内視鏡検査、S状結腸鏡検査など）
  • 診断（バイオマーカー検査、大腸内視鏡検査）
  • エンドユーザー別（病院・診療所、臨床検査室など）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の大腸がんスクリーニングと診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の大腸がんスクリーニングと診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の大腸がんスクリーニングと診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の大腸がんスクリーニングと診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの大腸がんスクリーニングと診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の大腸がんスクリーニングと診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc
• FUJIFILM Holdings Corporation
• Novigenix SA
• QuidelOrtho Corporation
• Olympus Corporation
• Lepu Medical Technology（Beijing）Co., Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Colorectal Cancer Screening and Diagnostic Market was valued at USD 15.08 Billion in 2024 and is expected to reach USD 20.63 Billion in the forecast period with a CAGR of 5.34% through 2030. The Global Colorectal Cancer Screening and Diagnostic Market is witnessing significant growth due to increasing global awareness regarding cancer prevention, early detection, and advancements in diagnostic technologies. Rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Governments and healthcare organizations are launching awareness campaigns that emphasize the importance of routine screening, contributing to a surge in testing volumes. Public-private partnerships and healthcare funding initiatives are enabling greater access to diagnostic services, especially in underserved populations. Moreover, the growing acceptance of non-invasive screening methods such as fecal immunochemical tests (FIT), fecal DNA tests, and blood-based diagnostics is making screening more accessible and acceptable to a broader patient demographic.

Technological innovations are playing a vital role in reshaping the market landscape. The development of AI-based colonoscopy systems, digital pathology tools, and liquid biopsy technologies is improving detection accuracy and reducing the need for invasive procedures. Integration of machine learning in diagnostic imaging is assisting clinicians in identifying polyps and early-stage tumors more effectively. Rising interest in home-based and point-of-care testing options is also transforming patient behavior, with more individuals opting for convenient, self-administered diagnostic tools. Leading diagnostic companies are investing in research to enhance biomarker-based screening approaches that offer higher specificity and sensitivity, which is opening new revenue streams. The emergence of multi-cancer detection panels, which include colorectal cancer markers, is expected to further stimulate innovation and competition within the industry.

Key Market Drivers

Advancements in Technology

High-definition (HD) colonoscopy utilizes advanced imaging technology to provide clearer and more detailed images of the colon, enhancing the detection of precancerous polyps and early-stage colorectal cancer during procedures. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were 142,462 reported cases of colon and rectum cancer in the United States, emphasizing the importance of improved detection methods.

Key Market Challenges

False Positives and Over diagnosis

False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Over diagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Over diagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life.

Key Market Trends

Shift Towards Non-Invasive Tests

Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.

Key Market Players

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Novigenix SA
• FUJIFILM Holdings Corporation
• Olympus Corporation
• QuidelOrtho Corporation

Report Scope:

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, By Screening:

• Stool-Based Test
• Colonoscopy and Sigmoidoscopy
• Others

Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:

• Biomarker Test
• Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, By End User:

• Hospitals and Clinics
• Clinical Laboratories
• Others

Colorectal Cancer Screening and Diagnostic Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Screening and Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
  • 5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
  • 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Screening
  • 6.2.2. By Diagnostics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Screening
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By End User
  • 6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Screening
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Screening
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Screening
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Screening
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By End User

7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Screening
  • 7.2.2. By Diagnostics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Screening
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Screening
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Screening
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Screening
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Screening
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By End User

8. North America Colorectal Cancer Screening and Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Screening
  • 8.2.2. By Diagnostics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Screening
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Screening
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Screening
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By End User

9. South America Colorectal Cancer Screening and Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Screening
  • 9.2.2. By Diagnostics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Screening
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Screening
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Screening
      • 9.3.3.2.2. By Diagnostics
      • 9.3.3.2.3. By End User

10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Screening
  • 10.2.2. By Diagnostics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Screening
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Screening
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Screening
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Clinical Genomics Technologies Pty Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Danaher Corporation
• 16.3. DiaCarta, Inc
• 16.4. Eiken Chemical Co., Ltd.
• 16.5. Epigenomics AG
• 16.6. Freenome Holdings, Inc.
• 16.7. Guardant Health, Inc
• 16.8. FUJIFILM Holdings Corporation
• 16.9. Novigenix SA
• 16.10. QuidelOrtho Corporation
• 16.11. Olympus Corporation
• 16.12. Lepu Medical Technology (Beijing) Co., Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer